Stem cell tourism is criticized on grounds of consumer fraud, blatant lack of scientific
justification, and patient safety. However, the issues are complex because they invoke
questions concerning the limits of acceptable medical innovation and medical travel. Here
we discuss these issues and articulate conditions under which “unproven” therapies may be
offered to patients outside of regular clinical trials.